Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
Más filtros

Tipo del documento
Intervalo de año de publicación
1.
PLoS One ; 16(3): e0247467, 2021.
Artículo en Inglés | MEDLINE | ID: mdl-33690696

RESUMEN

This study aimed to investigate the effectiveness of leaf ethanolic extract of Etlingera hemisphaerica (LE3H) in reducing defects in fetal anatomy and endochondral ossification in mice induced by HgCl2 during the post-implantation period. Pregnant mice were divided into four groups, each consisting of 10 dams, and received drink and food ad libitum. The first group was administered LE3H (E1), the second one HgCl2 (E2), the third one HgCl2+LE3H (E3), and the fourth was control (E0), administered double-distilled water only. HgCl2 (5 mg/kg bw) was administrated by injection intraperitoneally on gestation day (GD)9 and LE3H (0.39 mg/g bw) was administered by gavage on GD10. The treated and control animals were killed by cervical dislocation on GD18, dissected, and the morphologically normal living fetuses (MNLF) were collected. The MNLF of E0, E1, E2, and E3 from 5 dams were fixed with Bouin solution, and observed using the free hand razor blade technique for soft tissue examination. The remaining MNLF were fixed with 96% ethanol, and then stained with Alizarin Red S and Alcian Blue for ossification examination. Index of length of ossified part (ILOP) of humerus, index of width of ossified part (IWOP) of humerus, ILOP of femur, and IWOP of femur were calculated. E2 had higher cases of anatomical defects (74,6%) than E3 (48.9%), E1 (15.0%), and E0 (0%). E2 had humerus IWOP of 0.82±0.03, which was significantly lower than that of E0 (0.89±0.04) and E1 (0.89±0.03), while that of E1 and E0 was not significantly different from each other. Meanwhile, IWOP in E3 (0.88±0.03) was significantly higher than that in E2, but not different from that in E1 and E0. Thus, LE3H mitigated defects in fetal anatomy and endochondral ossification induced by HgCl2 in mice.


Asunto(s)
Etanol/administración & dosificación , Enfermedades Fetales/prevención & control , Cloruro de Mercurio/efectos adversos , Osteogénesis/efectos de los fármacos , Zingiberaceae/química , Animales , Implantación del Embrión , Etanol/química , Etanol/farmacología , Femenino , Enfermedades Fetales/inducido químicamente , Feto/efectos de los fármacos , Inyecciones Intraperitoneales , Ratones , Extractos Vegetales , Hojas de la Planta/química , Embarazo
2.
Food Funct ; 9(5): 2634-2643, 2018 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-29561026

RESUMEN

Sodium valproate (VPA) is an anti-epileptic drug, but has a strong embryotoxicity due to its induced disturbance of folate-homocysteine (Hcy) metabolism and fatty acid metabolism. The aim of the present study was to investigate whether polyunsaturated fatty acid (PUFA) intake during pregnancy can relieve the embryotoxicity of VPA. VPA (dose: 500 mg kg-1, concentration: 38.5 mg ml-1) was intraperitoneally injected into pregnant mice on day 8.5 of gestation (E8.5d). PUFA intake significantly decreased fetal mortality and NTD incidence induced by VPA: n-3 long chain PUFAs (n-3 LCPUFAs) in fish oil had the best decreasing effect, followed by C18:3n-3 in flaxseed oil and then C18:2n-6 in corn oil. VPA administration inhibited the mRNA and protein expressions of a series of enzymes involved in folate-Hcy metabolism in the liver of pregnant mice; however, it led to the mRNA and protein overexpression of these enzymes in embryos. An elevated Hcy level in embryos was observed 6 h after VPA injection. n-3 PUFA intake effectively relieved this disturbance of folate-Hcy metabolism in pregnant mice and embryos, and this relieving effect of n-3 LCPUFAs and C18:3n-3 is better than that of C18:2n-6. In addition, n-3 PUFA intake also relieved the growth retardation induced by VPA. In conclusion, PUFA intake during pregnancy can effectively decrease embryotoxicity of VPA by relieving VPA-induced disturbance of folate-Hcy metabolism in pregnant mice and embryos, and n-3 LCPUFA in fish oil had the optimal protection effect.


Asunto(s)
Anticonvulsivantes/toxicidad , Desarrollo Embrionario/efectos de los fármacos , Ácidos Grasos Omega-3/administración & dosificación , Enfermedades Fetales/prevención & control , Ácido Valproico/toxicidad , Animales , Anticonvulsivantes/uso terapéutico , Femenino , Enfermedades Fetales/metabolismo , Ácido Fólico/metabolismo , Homocisteína/metabolismo , Humanos , Masculino , Ratones , Ratones Endogámicos ICR , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Complicaciones del Embarazo/metabolismo , Convulsiones/tratamiento farmacológico , Convulsiones/metabolismo , Ácido Valproico/uso terapéutico
3.
Folia Morphol (Warsz) ; 77(1): 1-15, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-28703846

RESUMEN

BACKGROUND: In spite of its industrial usefulness and varied daily uses, lead (Pb) pollution is a widespread ecological problem that faces the humans in the 21th century. Pb was found to produces a wide range of toxic effects including neurotoxicity especially to the developing and young offspring. Recently, the utilisation of herbal plants has received a significant attention where there has been rising awareness in their therapeutic use; among these is the garlic. In light of the above, the current study is designed experimentally in female pregnant rats in order to investigate the beneficial role of garlic extract in the protection from the maternal and foetal cerebellar damage produced by administration of different doses of Pb during pregnancy. MATERIALS AND METHODS: Positively pregnant female rats were divided into five groups; one control group, two Pb-treated groups (exposed to 160 and 320 mg/kg b.w. of Pb, respectively) and two groups treated with both Pb and garlic (exposed to Pb as previous groups together with 250 mg/kg b.w./day of garlic extract). Treatments started from day 1 to day 20 of pregnancy, where the mother rats of different experimental groups were sacrificed to obtain the foetuses. Pb level in the maternal and foetal blood and cerebellum was estimated by spectrophotometry. Specimens of the cerebellum of different mother and foetal groups were processed to histological and immunohistochemical staining for microscopic examination. RESULTS: The results showed that administration of Pb to pregnant rats resulted in a dose-dependent toxicity for both mothers and foetuses in the form of decrease in maternal weight gain, placental and foetal weights, brain weight and diminished foetal growth parameters, which were prominent in rat's group treated with larger dose of Pb. In Pb-treated rats, Pb level in blood and cerebellum was high when compared with the control group. The histopathological examination of the cerebellum of treated dams and foetuses showed marked alterations mainly in the form of Purkinje cell degeneration and lack of development of foetal cerebellum. Co-treatment of garlic extract along with Pb resulted in a significant decrease in Pb levels as compared with those treated with Pb alone with improvement of the histopathological changes. CONCLUSIONS: This study was useful in evaluating the hazardous effects of uncontrolled use of Pb in general and in assessing the developmental and neurotoxicity of foetuses due to exposure during pregnancy in particular. Co-administration of garlic has beneficial effects in amelioration of Pb-induced neurotoxicity and reversing the histopathological changes of the cerebellum of mother rats and foetuses. (Folia Morphol 2018; 77, 1: 1-15).


Asunto(s)
Lesiones Encefálicas , Enfermedades Fetales , Ajo/química , Intoxicación por Plomo , Plomo , Exposición Materna/efectos adversos , Extractos Vegetales/farmacología , Animales , Lesiones Encefálicas/inducido químicamente , Lesiones Encefálicas/embriología , Lesiones Encefálicas/patología , Lesiones Encefálicas/prevención & control , Cerebelo/embriología , Cerebelo/patología , Femenino , Enfermedades Fetales/inducido químicamente , Enfermedades Fetales/patología , Enfermedades Fetales/prevención & control , Intoxicación por Plomo/embriología , Intoxicación por Plomo/patología , Intoxicación por Plomo/prevención & control , Extractos Vegetales/química , Embarazo , Ratas
4.
Best Pract Res Clin Endocrinol Metab ; 29(3): 385-98, 2015 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-26051298

RESUMEN

Calcium and phosphorus represent building material for bones. The supplier of these bone minerals is the hormone calcitriol, which originates from vitamin D, itself made by sunshine in human skin. Requirement for bone minerals is highest during phases of rapid growth, and no one grows faster than the foetus and the infant, making them particularly vulnerable. Deprivation of calcium, whether through low calcium intake or low vitamin D, leads to serious health consequences throughout life, such as hypocalcaemic seizures, dilated cardiomyopathy, skeletal myopathy, congenital and infantile rickets, and osteomalacia. These 5 conditions are often summarised as 'symptomatic vitamin D deficiency', are fully reversible but also fully preventable. However, the increasing prevalence of rickets and osteomalacia, and the deaths from hypocalcaemic cardiomyopathy, demand action from global health care providers. Clarification of medical and parental responsibilities is a prerequisite to deliver successful prevention programmes. The foetus and infant have the human right to be protected against harm, and vitamin D supplementation has the same public health priority as vaccinations.


Asunto(s)
Calcio de la Dieta/uso terapéutico , Calcio/deficiencia , Cardiomiopatía Dilatada/prevención & control , Osteomalacia/prevención & control , Complicaciones del Embarazo/prevención & control , Raquitismo/prevención & control , Convulsiones/prevención & control , Deficiencia de Vitamina D/prevención & control , Vitaminas/uso terapéutico , Calcitriol/uso terapéutico , Cardiomiopatía Dilatada/etiología , Colecalciferol/uso terapéutico , Ergocalciferoles/uso terapéutico , Femenino , Enfermedades Fetales/etiología , Enfermedades Fetales/prevención & control , Humanos , Lactante , Recién Nacido , Osteomalacia/etiología , Embarazo , Raquitismo/congénito , Raquitismo/etiología , Convulsiones/etiología , Deficiencia de Vitamina D/complicaciones
5.
Ginekol Pol ; 86(1): 62-6, 2015 Jan.
Artículo en Polaco | MEDLINE | ID: mdl-25775877

RESUMEN

The scientific goals related to the grant include 1) estimation of FNAIT prevalence in Poland and 2) search for biomarkers to predict the risk of the antibody production and severity of fetal thrombocytopenia. Fetal/Neonatal Alloimmune Thrombocytopenia (FNAIT) is caused by destruction of fetal blood platelets due to maternal antibodies. This condition, which most commonly results from incompatibility between the mother and the fetus for the Human Platelet Antigen-1a (HPA-1a), may lead to intracranial hemorrhage, damage of the central nervous system (CNS) and even death of the fetus or the newborn. It can be the cause of strokes in term newborns. FNAIT is usually attributed to the presence of anti-HPA-1a antibodies. Its incidence rate is estimated at approximately 1/1000-2000 live births. In the absence of a screening program, it is usually diagnosed after birth of a child with symptoms of thrombocytopenia or CNS hemorrhage. Monitoring of antibody production and thrombocytopenia treatment to effectively minimize the risk of stroke are therefore launched only at the next pregnancy. Testing indications are broader to include fetal ultrasound for symptoms of stroke to the CNS, ventricular enlargement or hydrocephalus, and obstetric failure. Diagnostic process is also recommended prior to the planned cordocentesis, in vitro fertilization and in sisters of mothers with children with FNAIT history. HPA-1a testing remains the best method for diagnosing pregnancies at risk. The detection frequency for FNAIT in Poland remains low. Therefore, the Institute of Hematology and Transfusion Medicine (IHTM) will have performed such HPA-1a antigen testing in 30 000 Polish women within the framework of the PREVFNAIT program by March 2016. HPA-1a negative women (2% of the population) are a risk group for production of anti- HPA-1a antibodies responsible for FNAIT therefore all of them will be monitored for the presence and activity of anti-HPA-1a antibodies. Such testing will be performed free of charge for the women.


Asunto(s)
Enfermedades Fetales/diagnóstico , Enfermedades Fetales/prevención & control , Servicios de Salud Materna/organización & administración , Prevención Primaria/organización & administración , Trombocitopenia Neonatal Aloinmune/diagnóstico , Trombocitopenia Neonatal Aloinmune/prevención & control , Femenino , Enfermedades Fetales/diagnóstico por imagen , Humanos , Incidencia , Programas Nacionales de Salud/organización & administración , Polonia/epidemiología , Embarazo , Atención Prenatal/organización & administración , Prevalencia , Medición de Riesgo/organización & administración , Trombocitopenia Neonatal Aloinmune/diagnóstico por imagen , Trombocitopenia Neonatal Aloinmune/epidemiología , Ultrasonografía
6.
Reprod Toxicol ; 49: 185-95, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-25246140

RESUMEN

Maternal diabetes induces a pro-oxidant/pro-inflammatory intrauterine environment related to the induction of congenital anomalies. Peroxisome proliferator activated receptors (PPARs) are transcription factors that regulate antioxidant and anti-inflammatory pathways. We investigated whether maternal diets supplemented with olive oil, enriched in oleic acid, a PPAR agonist, can regulate the expression of PPAR system genes, levels of lipoperoxidation and activity of matrix metalloproteinases (MMPs) and their endogenous inhibitors (TIMPs) in embryos and decidua from diabetic rats. The embryos and decidua from diabetic rats showed reduced expression of PPARs and increased concentration of lipoperoxidation, MMPs and TIMPs, whereas the maternal treatments enriched in olive oil increased PPARδ in embryos and PPARγ and PPARγ-coactivator-1α expression in decidua, and increased TIMPs concentrations and decreased lipoperoxidation and MMPs activity in both tissues. Thus, maternal diets enriched in olive oil can regulate embryonic and decidual PPAR system genes expression and reduce the pro-oxidant/pro-inflammatory environment during rat early organogenesis.


Asunto(s)
Enfermedades Fetales/prevención & control , Aceite de Oliva/efectos adversos , Embarazo en Diabéticas/tratamiento farmacológico , Animales , Decidua/efectos de los fármacos , Suplementos Dietéticos , Femenino , Enfermedades Fetales/etiología , Feto/efectos de los fármacos , Metaloproteinasas de la Matriz/efectos de los fármacos , Aceite de Oliva/administración & dosificación , Estrés Oxidativo/efectos de los fármacos , Receptores Activados del Proliferador del Peroxisoma/efectos de los fármacos , Embarazo , Ratas , Ratas Wistar
7.
Endocrinol Nutr ; 61(1): 27-34, 2014 Jan.
Artículo en Inglés, Español | MEDLINE | ID: mdl-24035326

RESUMEN

Severe and mild iodine deficiency during pregnancy and lactation affects thyroid function of the mother and neonate as well as the infant's neuropsychological development. Studies performed in Spain confirm that most women are iodine deficient during pregnancy and lactation. Pregnant and breast feeding women and women planning to become pregnant should take iodine supplements.


Asunto(s)
Suplementos Dietéticos , Hipotiroidismo/prevención & control , Compuestos de Yodo/uso terapéutico , Yodo/deficiencia , Lactancia , Complicaciones del Embarazo/prevención & control , Ensayos Clínicos Controlados como Asunto , Enfermedades Carenciales/sangre , Enfermedades Carenciales/dietoterapia , Enfermedades Carenciales/tratamiento farmacológico , Enfermedades Carenciales/epidemiología , Enfermedades Carenciales/prevención & control , Suplementos Dietéticos/efectos adversos , Femenino , Sangre Fetal/química , Desarrollo Fetal/efectos de los fármacos , Enfermedades Fetales/etiología , Enfermedades Fetales/prevención & control , Aditivos Alimentarios , Humanos , Hipotiroidismo/etiología , Recién Nacido , Yodo/metabolismo , Yodo/uso terapéutico , Compuestos de Yodo/administración & dosificación , Compuestos de Yodo/efectos adversos , Compuestos de Yodo/farmacología , Necesidades Nutricionales , Embarazo , Complicaciones del Embarazo/tratamiento farmacológico , Complicaciones del Embarazo/etiología , Trastornos Puerperales/inducido químicamente , Alimentos Marinos , Cloruro de Sodio Dietético/uso terapéutico , España/epidemiología , Tiroiditis/inducido químicamente , Tirotropina/sangre
8.
Minerva Ginecol ; 65(4): 471-84, 2013 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-24051947

RESUMEN

Screening for thyroid disease in pregnancy remains a contentious issue. This review presents these diverging views and discusses their reasons as well as the relevant facts. The final aim is to establish the information gaps and limitations - technological or otherwise - which still need to be eliminated in order to settle the debate conclusively. The prevalence of the more common thyroid dysfunctions that occur in and after pregnancy is discussed. The subsequent impact of these disorders on mother and offspring is also described. Special focus is placed on the benefits and setbacks of currently available and newly proposed investigations, which assay serum hormone levels, serum autoantibody levels, and/or use clinical data. It is pointed out that the relevance of screening varies from one region of the world to the other, based on the content of iodine and selenium in food and water. The review then discusses the current major arguments for and against screening, as well as recommendations and proposed alternatives.


Asunto(s)
Tamizaje Masivo/métodos , Complicaciones del Embarazo/diagnóstico , Atención Prenatal/métodos , Enfermedades de la Tiroides/diagnóstico , Aborto Espontáneo/etiología , Aborto Espontáneo/prevención & control , Autoanticuerpos/sangre , Femenino , Enfermedades Fetales/diagnóstico , Enfermedades Fetales/etiología , Enfermedades Fetales/prevención & control , Humanos , Recién Nacido , Yodo/deficiencia , Tamizaje Neonatal , Guías de Práctica Clínica como Asunto , Embarazo , Complicaciones del Embarazo/sangre , Complicaciones del Embarazo/epidemiología , Diagnóstico Prenatal , Trastornos Puerperales/diagnóstico , Trastornos Puerperales/epidemiología , Trastornos Puerperales/prevención & control , Ingesta Diaria Recomendada , Valores de Referencia , Selenio/deficiencia , Sensibilidad y Especificidad , Enfermedades de la Tiroides/sangre , Enfermedades de la Tiroides/congénito , Enfermedades de la Tiroides/epidemiología , Glándula Tiroides/diagnóstico por imagen , Hormonas Tiroideas/sangre , Tirotropina/sangre , Ultrasonografía
9.
Fetal Diagn Ther ; 34(3): 180-3, 2013.
Artículo en Inglés | MEDLINE | ID: mdl-23860191

RESUMEN

Gestational alloimmune liver disease occurs due to trans-placental passage of maternal antibodies to a fetal hepatocyte antigen that produces complement-mediated hepatocyte injury. High-dose intravenous immunoglobulin therapy during gestation is highly effective at decreasing the risk to the neonate but treatment is expensive. This case presents for the first time the use of plasmapheresis as a potential cheaper alternative when treatment with immunoglobulins is unavailable.


Asunto(s)
Enfermedades Fetales/prevención & control , Hemocromatosis/prevención & control , Inmunoglobulinas Intravenosas/uso terapéutico , Hepatopatías/prevención & control , Plasmaféresis , Adulto , Femenino , Humanos , Inmunoglobulinas Intravenosas/administración & dosificación , Embarazo
10.
Ginecol Obstet Mex ; 80(9): 563-80, 2012 Sep.
Artículo en Español | MEDLINE | ID: mdl-23243836

RESUMEN

BACKGROUND: According to data from the World Health Organization and UNICEF from year 2009, iron deficiency is the most widespread nutritional deficiency worldwide. This deficiency causes an imbalance between needs and iron supply, which consequently results in anemia. Around the world, two million people suffer from anemia, half of which is due to iron deficiency. The most impacted groups are children and teenagers, due to their highest requirements derived from the growing process, and women in their reproductive age, due to their loss of iron derived from menstruating or to their highest iron needs during pregnancy. This increase in needs is not satisfied by the regular diet, since it includes an insufficient amount and/or low bioavailability of iron. PURPOSE: To share with the medical community treating pregnant women the experience of an expert group so that they always bear in mind the repercussions caused by anemia during pregnancy, know more about the diagnostic possibilities and have a reference point for prescribing iron supplements. METHOD: The consensus method was used through the expert panel group technique. Two rounds were taken for structuring the clinical questions. The first one was to facilitate working groups their focusing in the clinical topics and the population of interest; the second one was to aid in posing specific questions observing the Patient, Intervention, Compare and Outcome (PICO) structure. The primary and clinical secondary study variables were defined by the working groups from the previously developed questions and during the face-to-face working period, according to the natural history of the disease: risk factors, diagnostic classification, (either pharmacological or non pharmacological) treatment and prognosis. The level of evidence and clinical recommendation was classified based on the Evidence Classification Level and Clinical Recommendation of the Medicine Group based on Evidence from Oxford University. RESULTS: In Mexico, 20.6% of pregnant women suffer from anemia, especially those between 15 and 16 years old, who prevail in 42.4% and 34.3% percent, respectively. Almost half the cases are due to iron deficiency. This type of anemia is associated with a higher risk of pre-term delivery, of low birth weight and perinatal death. The first assessment of an anemic pregnant woman shall include the medical history, a physical examination and the quantification of the erythrocyte indices, serum concentrations of iron and ferritin. The measurement of this last one has the highest sensitivity and specificity for diagnosing iron deficiency. Daily oral iron supplementation, at a 60-to-120 mg dosage, may correct most of mild-to-moderate anemias. The most appropriate treatment is with iron salts (iron sulfate, polimaltose iron complex or iron fumarate). In case of intolerance to iron sulfate or fumarate, polimaltose iron is a better tolerated option. Treatment shall be administered until the hemoglobin values are > 10.5 g and ferritin is between 300 and 360 microg/dL, and such levels shall be observed for at least one year. Parenteral administration is an alternative for patients with a severe intolerance to oral administration; even when the possibility of anaphylaxis shall be considered it is lower when using ferrous sacarate. Transfusion is reserved for patients with hemoglobin lower than 7 g/dL or having an imminent cardio-respiratory decompensation. CONCLUSIONS: Iron deficiency is the highest prevailing nutritional deficiency worldwide and its consequences during pregnancy may be highly risky for both the mother and her child. Anemia diagnosis may easily be achieved through a blood analysis including the serum ferritin determination. Serum iron measurement shall not be used as the only marker to set the diagnosis. It is important to rule out other causes, in addition to the deficiencies, which produce anemia in a patient. It is essential to suggest the administration of iron supplements not only during the antenatal period but also after birth o even after a miscarriage to fulfill the need for depleted iron. In severe anemias (hemoglobin being lower than 9.0 g/L), iron doses higher than 120 mg a day may be required. Treatment shall always begin orally, and if this is not well tolerated, parenteral administration shall be used.


Asunto(s)
Anemia/diagnóstico , Anemia/tratamiento farmacológico , Complicaciones Hematológicas del Embarazo/diagnóstico , Complicaciones Hematológicas del Embarazo/tratamiento farmacológico , Adolescente , Adulto , Anemia/clasificación , Anemia/epidemiología , Anemia/etiología , Anemia/terapia , Anemia Ferropénica/diagnóstico , Anemia Ferropénica/tratamiento farmacológico , Anemia Ferropénica/epidemiología , Anemia Ferropénica/etiología , Anemia Ferropénica/terapia , Biomarcadores , Transfusión Sanguínea , Medicina Basada en la Evidencia , Femenino , Ferritinas/sangre , Muerte Fetal/etiología , Enfermedades Fetales/etiología , Enfermedades Fetales/prevención & control , Ácido Fólico/administración & dosificación , Ácido Fólico/uso terapéutico , Salud Global , Hemoglobinas/análisis , Humanos , Recién Nacido , Hierro/administración & dosificación , Hierro/efectos adversos , Hierro/sangre , Hierro/uso terapéutico , Hierro de la Dieta/farmacocinética , México/epidemiología , Persona de Mediana Edad , Atención Posnatal/métodos , Atención Posnatal/normas , Embarazo , Complicaciones Hematológicas del Embarazo/clasificación , Complicaciones Hematológicas del Embarazo/epidemiología , Complicaciones Hematológicas del Embarazo/etiología , Complicaciones Hematológicas del Embarazo/terapia , Atención Prenatal/métodos , Atención Prenatal/normas , Prevalencia , Factores de Riesgo , Sensibilidad y Especificidad , Índice de Severidad de la Enfermedad , Adulto Joven
11.
Nutrition ; 28(5): 581-7, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22189193

RESUMEN

OBJECTIVE: Diabetes during pregnancy increases the incidences of congenital anomalies, morbidity, and mortality in the mother and her fetus/newborn. Oxidative stress (OS) has been implicated to be responsible because various antioxidants have been demonstrated to be beneficial in diabetic embryopathy. In this study, we examined the propensity of Tinospora cordifolia (TC) to attenuate embryopathy and OS in pregnant diabetic rats. METHODS: Pregnant rats were rendered diabetic with streptozotocin (45 mg/kg of body weight, on gestation day 4) and fed a normal or a TC-supplemented (1% or 2%) diet. After monitoring diet intake, body weight gain, and urine output, dams were sacrificed on gestation day 20 and the markers of OS were determined in the maternal liver and the fetal brain and liver. RESULTS: Although streptozotocin induced a significant (40%) increase in embryopathy, the dietary supplements offered significant protection (63%). Interestingly, TC significantly offset the diabetes-associated OS in the maternal liver as evidenced by the lower levels of malondialdehyde (25%) and reactive oxygen species (72%) and the higher levels of glutathione (53%) and total thiols (45%). The protective effects of TC could be observed even in the fetal milieu, with higher levels of antioxidant molecules and enzymes. CONCLUSION: These data suggest that TC during pregnancy may provide significant protection against diabetes-induced OS and thus serve as an effective therapeutic supplement.


Asunto(s)
Diabetes Mellitus Experimental/tratamiento farmacológico , Suplementos Dietéticos , Estrés Oxidativo/efectos de los fármacos , Extractos Vegetales/farmacología , Complicaciones del Embarazo/tratamiento farmacológico , Tinospora/química , Animales , Antioxidantes/farmacología , Glucemia/efectos de los fármacos , Diabetes Mellitus Experimental/inducido químicamente , Diabetes Mellitus Experimental/fisiopatología , Dieta , Femenino , Enfermedades Fetales/tratamiento farmacológico , Enfermedades Fetales/prevención & control , Glutatión/sangre , Glutatión Peroxidasa/sangre , Masculino , Malondialdehído/sangre , Embarazo , Complicaciones del Embarazo/inducido químicamente , Complicaciones del Embarazo/fisiopatología , Ratas , Ratas Wistar , Especies Reactivas de Oxígeno/metabolismo , Superóxido Dismutasa/sangre
12.
Eur J Clin Pharmacol ; 68(5): 455-8, 2012 May.
Artículo en Inglés | MEDLINE | ID: mdl-22076561

RESUMEN

OBJECTIVE: We describe clinical trials conducted in pregnant women. METHODS: We searched PubMed database for articles related to clinical trials between 01/01/2000 and 31/12/2009 involving pregnant women by using the preferred terms "pregnancy", "human", and "clinical trials". RESULTS: Of 1,264 retrieved publications, 762 (60%) were excluded, leaving 502 for analysis: 53% were preventive studies in maternal or fetal conditions; 47% were therapeutic trials, mostly focused on acute obstetric diseases; 66% were assigned a pharmacological intervention. The studied drugs were 16% for labour induction and 15% for abortive procedures, followed by multivitamins and micronutrients, labour analgesia and anesthesia, antibiotics, tocolytics, and antimalarial drugs. The main objectives of the studies were focused on efficacy (54%) and efficacy and safety (26%); 81% of the studies were controlled, randomized and parallel-design trials; 19% were blinded. CONCLUSION: Clinical trials in pregnant women are mainly conducted with an efficacy objective regarding maternal-fetal prevention and in obstetric diseases to study labor induction and abortive measures. This is in line with the type of intervention and drugs involved.


Asunto(s)
Ensayos Clínicos como Asunto , Enfermedades Fetales/prevención & control , Complicaciones del Embarazo/prevención & control , Abortivos/efectos adversos , Aborto Inducido/efectos adversos , Aborto Inducido/métodos , Ensayos Clínicos como Asunto/efectos adversos , Ensayos Clínicos como Asunto/normas , Suplementos Dietéticos/efectos adversos , Femenino , Enfermedades Fetales/terapia , Humanos , Trabajo de Parto Inducido/efectos adversos , Trabajo de Parto Inducido/métodos , Fenómenos Fisiologicos Nutricionales Maternos , Oxitócicos/efectos adversos , Guías de Práctica Clínica como Asunto , Embarazo , Complicaciones del Embarazo/terapia
13.
J Am Acad Dermatol ; 65(6): 1117-25, 2011 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21565419

RESUMEN

BACKGROUND: Preventing fetal exposure to isotretinoin is widely acknowledged as an important safety issue. The iPLEDGE program is the latest in a series of Food and Drug Administration-mandated risk management programs designed to prevent pregnancies in female patients of childbearing potential (FCBP) taking isotretinoin. OBJECTIVE: We sought to evaluate the effect of iPLEDGE relative to the prior risk management program (system to manage Accutane-related teratogenicity [SMART]) on the risk of isotretinoin fetal exposure in FCBP in a managed care setting. METHODS: All FCBP at Kaiser Permanente Southern and Northern California who filled at least one prescription for isotretinoin during a 4-year period (March 1, 2004, to February 29, 2008) were included in this retrospective cohort study (n = 8344). Chart review was performed to confirm fetal exposures and outcomes. A Cox proportional hazards model was used to estimate the hazard ratio and 95% confidence intervals. RESULTS: There were a total of 29 fetal exposures and 9912 isotretinoin treatment courses. After iPLEDGE was implemented, the unadjusted rate of fetal exposure decreased from 3.11 to 2.67 per 1000 treatment courses (P = .69). The hazard ratio = 0.76 (95% confidence interval 0.36-1.61) for fetal exposures to isotretinoin during treatment courses filled after iPLEDGE implementation compared with SMART. LIMITATIONS: Limitations include limited generalizability of results, small sample size (n = 29 total documented fetal exposures), and potential uncontrolled confounders. CONCLUSION: Evaluating the impact of iPLEDGE on isotretinoin fetal exposures is important in understanding the full risks and benefits of isotretinoin treatment. We found no evidence that iPLEDGE significantly decreased the risk of fetal exposure in FCBP compared to the SMART program.


Asunto(s)
Fármacos Dermatológicos/efectos adversos , Enfermedades Fetales/prevención & control , Isotretinoína/efectos adversos , Adolescente , Adulto , Estudios de Cohortes , Prestación Integrada de Atención de Salud , Enfermedades Fetales/inducido químicamente , Humanos , Evaluación de Programas y Proyectos de Salud , Estudios Retrospectivos , Gestión de Riesgos , Adulto Joven
14.
J Matern Fetal Neonatal Med ; 24(10): 1259-61, 2011 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-21504338

RESUMEN

OBJECTIVE: The aim of this study was to demonstrate the neuroprotective effect of magnesium sulfate on ischemia-reperfusion-induced injury in fetal rat brain. METHODS: Twenty-four, 19-days pregnant rats were randomly allocated into four groups. Fetal brain ischemia was induced by clamping the utero-ovarian artery bilaterally for 20 min and reperfusion was achieved by removing the clamps for 30 min. The control group consisted of noninjured rats. No treatment was given in the ischemia-reperfusion group; whereas 1 ml saline and 600 mg/kg magnesium sulfate was administered in the vehicle and the treatment groups 30 min before ischemia reperfusion injury. Lipid peroxidation in the brain tissue was determined as the concentration of thiobarbituric acid-reactive substances (TBARS) for each fetal rat. A one-way analysis of variance and post hoc test were used for statistical analysis. RESULTS: TBARS levels were found to be increased after ischemia reperfusion injury when compared with controls. Magnesium sulfate treatment prevented the increase in TBARS after ischemia reperfusion injury. CONCLUSIONS: We have shown that magnesium sulfate decreases TBARS levels significantly in fetal rat brain subjected to ischemia reperfusion injury and may have potential therapeutic benefits by reducing oxidative stress after intrauterine ischemia-reperfusion-induced fetal brain damage.


Asunto(s)
Anticonvulsivantes/uso terapéutico , Lesiones Encefálicas/prevención & control , Enfermedades Fetales/prevención & control , Sulfato de Magnesio/uso terapéutico , Daño por Reperfusión/prevención & control , Animales , Lesiones Encefálicas/etiología , Isquemia Encefálica/complicaciones , Evaluación Preclínica de Medicamentos , Femenino , Embarazo , Ratas , Ratas Wistar
15.
Aust N Z J Obstet Gynaecol ; 50(4): 334-9, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20716260

RESUMEN

BACKGROUND: The Fetal Welfare Obstetric emergency Neonatal resuscitation Training (FONT) project was initiated on a background of rising notifications of adverse events in NSW maternity units, the significant proportion of which were related to fetal welfare assessment. AIMS: The aim of the study is to describe the development and introduction of the NSW state-wide interprofessional FONT project. METHODS: Following development and risk assessment, FONT was launched in February 2008. The project consists of an online component and two face-to-face training days to be completed each 3 years; the first day for fetal welfare assessment and the second for obstetric and newborn emergencies. Eight, 2-day training sessions were conducted throughout NSW for FONT trainers. Each trainer underwent pre- and post-testing for changes in knowledge of fetal welfare assessment. The 2005-2008 NSW adverse event report numbers were assessed. RESULTS: From 20 February to 17 April 2008, 240 trainers had been trained in fetal welfare assessment, and by the end of 2008 these trainers had trained 954 clinicians. There were significant improvements in the interpretation and management planning of electronic fetal heart rate patterns following training. Analysis of Severity Assessment Codes 1 and 2 showed no significant trend in the number of notifications for adverse events related to fetal welfare assessment. CONCLUSIONS: In the first 11 months, 25% of the state's maternity practitioners had received training in the first stage of the FONT project. The FONT project has shown short-term improvements in learning and communication skills and in the participants of the project.


Asunto(s)
Enfermedades Fetales/prevención & control , Frecuencia Cardíaca Fetal , Partería/educación , Obstetricia/educación , Complicaciones del Embarazo/prevención & control , Resucitación/educación , Enseñanza/métodos , Australia , Competencia Clínica , Educación Médica/métodos , Urgencias Médicas , Femenino , Monitoreo Fetal , Humanos , Recién Nacido , Relaciones Interprofesionales , Planificación de Atención al Paciente , Médicos , Embarazo , Evaluación de Programas y Proyectos de Salud
17.
J Matern Fetal Neonatal Med ; 23(8): 932-4, 2010 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-20459344

RESUMEN

During pregnancy skeletal lead is mobilized by maternal bone turnover and can threaten fetal development. The exact strategy suggested to women of childbearing age, who were chronically exposed to lead, and, thus, have high bone lead burden, is not well established. We describe 4 years of follow-up of a 29-year-old woman with chronic lead intoxication. We (a) advised her to delay conception until 'toxicological clearance', (b) treated her with multiple courses of lead chelator, DMSA, and (c) prescribed oral calcium. Patient had low blood lead and protoporphyrin level during pregnancy until delivery. Delaying conception, lead chelation, and calcium supplementation can decrease fetal exposure.


Asunto(s)
Quelantes/uso terapéutico , Enfermedades Fetales/prevención & control , Intoxicación por Plomo/tratamiento farmacológico , Efectos Tardíos de la Exposición Prenatal/prevención & control , Succímero/uso terapéutico , Adulto , Calcio/uso terapéutico , Femenino , Humanos , Intoxicación por Plomo/prevención & control , Embarazo
18.
Mol Hum Reprod ; 16(4): 286-95, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20051498

RESUMEN

Aberrant arachidonic acid and nitric oxide (NO) metabolic pathways are involved in diabetic embryopathy. Previous works have found diminished concentrations of PGE(2) and PGI(2) in embryos from diabetic rats, and that PGI(2) is capable of increasing embryonic PGE(2) concentrations through the activation of the nuclear receptor PPARdelta. PPARdelta activators are lipid molecules such as oleic and linoleic acids, present in high concentrations in olive and safflower oils, respectively. The aim of this study was to analyze the capability of dietary supplementation with either 6% olive or 6% safflower oils to regulate PGE(2), PGI(2) and NO concentrations in embryos and deciduas from control and diabetic rats during early organogenesis. Diabetes was induced by a single injection of streptozotocin (55 mg/kg) 1 week before mating. Animals were fed with the oil-supplemented diets from Days 0.5 to 10.5 of gestation. PGI(2) and PGE(2) were measured by EIA and NO through the evaluation of its stable metabolites nitrates-nitrites in 10.5 day embryos and deciduas. We found that the olive and safflower oil-supplemented treatments highly reduced resorption and malformation rates in diabetic animals, and that they were able to prevent maternal diabetes-induced alterations in embryonic and decidual PGI(2) and PGE(2) concentrations. Moreover, these dietary treatments prevented NO overproduction in embryos and deciduas from diabetic rats. These data indicate that in maternal diabetes both the embryo and the decidua benefit from the olive and safflower oil supplementation probably through mechanisms that involve the rescue of aberrant prostaglandin and NO generation and that prevent developmental damage during early organogenesis.


Asunto(s)
Ácido Araquidónico/metabolismo , Grasas de la Dieta/administración & dosificación , Suplementos Dietéticos , Enfermedades Fetales/prevención & control , Óxido Nítrico/metabolismo , Aceites de Plantas/administración & dosificación , Aceite de Cártamo/administración & dosificación , Animales , Diabetes Mellitus Experimental/metabolismo , Dinoprostona/metabolismo , Embrión de Mamíferos/metabolismo , Femenino , Masculino , Modelos Biológicos , Aceite de Oliva , Embarazo , Embarazo en Diabéticas , Ratas , Ratas Wistar
19.
Endocrinol Nutr ; 56(1): 9-12, 2009 Jan.
Artículo en Español | MEDLINE | ID: mdl-19627703

RESUMEN

OBJECTIVE: Several studies performed in Spain have reported iodine deficiency in pregnant women but data from Valencia are lacking. The aim of the present study was to determine the degree of implantation of iodine supplementation in pregnant women in our health area. PATIENTS AND METHOD: A total of 232 pregnant women were studied in the first trimester of pregnancy. Thyroid-stimulating hormone (TSH), free thyroxine, and antiperoxidase antibodies were measured. A survey was performed on intake of iodized salt and pharmacological iodine supplements. Neonatal TSH concentrations were measured, based on screening of metabolopathies, in the newborns of participating women. RESULTS: Then mean age was 30.5+/-4.4 years. A total of 60.8% of the women consumed iodized salt, 51.3% took iodine polyvitamins and only 14.2% consumed potassium iodide. The median urinary iodine concentration was 100 microg/l; 66% had urinary iodine concentrations below the recommended level (150 microg/l). A positive association was found between pharmacological iodine intake and urinary iodine (p=0.016). Ten percent of the women had mild hypothyroxinemia, while 5.7% of the newborns had elevated TSH levels. CONCLUSIONS: Iodine intake in pregnant women in our health area is low, despite current recommendations. Our data support the need to promote the use of iodized salt in every home and to systematically administer potassium iodide supplements in all pregnant women.


Asunto(s)
Yodo/deficiencia , Primer Trimestre del Embarazo/sangre , Adulto , Autoanticuerpos/sangre , Suplementos Dietéticos , Utilización de Medicamentos , Desarrollo Embrionario , Femenino , Sangre Fetal/química , Enfermedades Fetales/prevención & control , Humanos , Recién Nacido , Yodo/orina , Necesidades Nutricionales , Yoduro de Potasio , Embarazo , Estudios Prospectivos , Cloruro de Sodio Dietético , Tirotropina/sangre , Tiroxina/sangre , Vitaminas
20.
Endocrinol Nutr ; 56(2): 85-91, 2009 Feb.
Artículo en Español | MEDLINE | ID: mdl-19627716

RESUMEN

Subclinical thyroid disease is a biochemical diagnosis and is common during pregnancy. Because of the physiological hormonal changes that take place during pregnancy and the absence of normal ranges for thyroid hormones during this period, subclinical thyroid disease is difficult to interpret during pregnancy. Subclinical hyperthyroidism during pregnancy has few clinical consequences and no treatment is required. In contrast, subclinical hypothyroidism seems to improve with thyroxine treatment. Iodine supplements during pregnancy and lactation, even in iodine-sufficient areas, are also indicated.


Asunto(s)
Hipertiroidismo/diagnóstico , Hipertiroidismo/tratamiento farmacológico , Hipotiroidismo/diagnóstico , Hipotiroidismo/tratamiento farmacológico , Complicaciones del Embarazo/diagnóstico , Complicaciones del Embarazo/tratamiento farmacológico , Adulto , Desarrollo Embrionario , Femenino , Enfermedades Fetales/etiología , Enfermedades Fetales/prevención & control , Humanos , Hipertiroidismo/sangre , Hipotiroidismo/sangre , Yodo/administración & dosificación , Yodo/deficiencia , Yodo/uso terapéutico , Lactancia , Necesidades Nutricionales , Embarazo , Complicaciones del Embarazo/sangre , Trastornos Puerperales/tratamiento farmacológico , Hormonas Tiroideas/sangre , Tiroiditis Autoinmune/sangre , Tiroiditis Autoinmune/diagnóstico , Tiroiditis Autoinmune/tratamiento farmacológico , Tirotropina/sangre , Tiroxina/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA